TransCode Therapeutics's total assets for Q1 2025 were $13.19M, an increase of 80.88% from the previous quarter. RNAZ total liabilities were $2.90M for the fiscal quarter, a -68.84% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.